Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Inovio Pharmaceuticals, Inc.

Market Cap 90.95M 78.46M 72.14M 67.9M 128M 8.58B 129M 855M 333M 4.21B 341M 334M 14.57B P/E 2026 *
-1.24x
P/E 2027 * -2.88x
Enterprise Value 90.95M 78.46M 72.14M 67.9M 128M 8.58B 129M 855M 333M 4.21B 341M 334M 14.57B EV / Sales 2026 *
8.36x
EV / Sales 2027 * 1.32x
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 week+1.83%
Current month-15.27%
1 month-14.62%
3 months-33.93%
6 months-57.31%
Current year-36.21%
1 week 1.08
Extreme 1.085
1.15
1 month 1.06
Extreme 1.06
1.45
Current year 1.03
Extreme 1.03
2.03
1 year 1.03
Extreme 1.03
2.98
3 years 1.03
Extreme 1.03
14.75
5 years 1.03
Extreme 1.03
119.52
10 years 1.03
Extreme 1.03
405.48
Manager TitleAgeSince
Chief Executive Officer 60 2022-05-09
Director of Finance/CFO 62 2002-05-31
Chief Tech/Sci/R&D Officer 60 2022-06-26
Director TitleAgeSince
Chairman 81 2019-01-02
Director/Board Member 69 2016-03-10
Director/Board Member 71 2017-12-05
Date Insider Type Main position Quantity % Market Cap.
May. 19Free

Director

76,000 0.0928%
May. 19Free

Director

76,000 0.0928%
May. 19Fiscal year

Chief Technology Officer

75,817 0.0925%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.83%-41.58%-81.03% 90.95M
-0.22%-1.14%-11.88%-13.09% 43.44B
+0.76%+9.42%+303.09%+540.82% 33.54B
-4.74%-6.31%+10.75%-20.99% 28.48B
-0.47%-0.35%+3.38%+31.20% 29.2B
+0.06%+4.36%+13.31%+21.11% 25.34B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.05B
-0.29%-4.40%+3.13%+1.69% 12.67B
+1.67%+1.35%+105.56%+81.16% 12.28B
Average -0.42%+1.38%+48.80%+74.10% 21.25B
Weighted average by Cap. -0.60%+1.35%+62.71%+105.07%

Financials

2026 *2027 *
Net sales 10.88M 9.39M 8.63M 8.12M 15.26M 1.03B 15.39M 102M 39.82M 504M 40.84M 39.96M 1.74B 69.07M 59.59M 54.79M 51.57M 96.9M 6.52B 97.71M 649M 253M 3.2B 259M 254M 11.07B
Net income -68.56M -59.15M -54.38M -51.18M -96.18M -6.47B -96.99M -644M -251M -3.18B -257M -252M -10.99B -45.76M -39.48M -36.29M -34.16M -64.19M -4.32B -64.73M -430M -167M -2.12B -172M -168M -7.33B
Net Debt - -
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Employees
112
Date Price Change Volume
26-06-17 1.110 $ 0.00% 1,109,160
26-06-16 1.110 $ +0.91% 1,357,584
26-06-15 1.100 $ 0.00% 911,869
26-06-12 1.100 $ 0.00% 1,113,083
26-06-11 1.100 $ +0.92% 1,419,017
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.110USD
Average target price
5.825USD
Spread / Average Target
+424.77%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!